Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
06/09/2022 | CRISPR Therapeutics AG | CRSP | Grant | Stock Option (Right to Buy) | 12k | $71.70 | $860.4k | | 06/09/2022 |
07/19/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 700 | $128.71 | $90.1k | See Footnote | 07/19/2021 |
07/19/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 1.3k | $127.36 | $168.6k | See Footnote | 07/19/2021 |
07/19/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 4.5k | $126.41 | $565.3k | See Footnote | 07/19/2021 |
07/19/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 3.5k | $125.67 | $440.3k | See Footnote | 07/19/2021 |
06/29/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 1.4k | $145.92 | $204.3k | | 06/28/2021 |
06/29/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 600 | $146.69 | $88k | | 06/28/2021 |
06/29/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 4.8k | $147.43 | $704.7k | | 06/28/2021 |
06/29/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 12.2k | $148.58 | $1.8M | | 06/28/2021 |
06/29/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 8k | $149.47 | $1.2M | | 06/28/2021 |
06/29/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 12.8k | $150.49 | $1.9M | | 06/28/2021 |
06/29/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 6.6k | $151.24 | $1M | | 06/28/2021 |
06/29/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 1.2k | $152.42 | $182.9k | | 06/28/2021 |
06/28/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 3.2k | $150.65 | $484.5k | | 06/28/2021 |
06/28/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 1.6k | $150.65 | $237.7k | See Footnote | 06/28/2021 |
06/28/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 6.4k | $151.49 | $970k | | 06/28/2021 |
06/28/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 3.1k | $151.49 | $476.3k | See Footnote | 06/28/2021 |
06/28/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 3.1k | $152.38 | $478.3k | | 06/28/2021 |
06/28/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 1.5k | $152.38 | $234.7k | See Footnote | 06/28/2021 |
06/28/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 4.5k | $153.54 | $693.8k | | 06/28/2021 |
06/28/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 2.2k | $153.54 | $340.5k | See Footnote | 06/28/2021 |
06/28/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 2.3k | $154.57 | $352.6k | | 06/28/2021 |
06/28/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 1.1k | $154.57 | $173k | See Footnote | 06/28/2021 |
06/28/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 268 | $155.27 | $41.6k | | 06/28/2021 |
06/28/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 132 | $155.27 | $20.5k | See Footnote | 06/28/2021 |
06/28/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 549 | $156.54 | $85.9k | | 06/28/2021 |
06/28/2021 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 269 | $156.54 | $42.1k | See Footnote | 06/28/2021 |
06/28/2021 | Monte Rosa Therapeutics, Inc. | | Conversion | Common Stock | 6.5M | $0.00 | $0 | By Versant Venture Capital VI, L.P. | 06/28/2021 |
06/28/2021 | Monte Rosa Therapeutics, Inc. | | Conversion | Common Stock | 1.9M | $0.00 | $0 | By Versant Vantage I, L.P. | 06/28/2021 |
06/28/2021 | Monte Rosa Therapeutics, Inc. | | Purchase | Common Stock | 157.9k | $19.00 | $3M | By Versant Vantage I, L.P. | 06/28/2021 |
06/28/2021 | Monte Rosa Therapeutics, Inc. | | Conversion | Series A convertible preferred stock | 20M | $0.00 | $0 | By Versant Capital VI, L.P. | 06/28/2021 |
06/28/2021 | Monte Rosa Therapeutics, Inc. | | Conversion | Series B convertible preferred stock | 3M | $0.00 | $0 | By Versant Capital VI, L.P. | 06/28/2021 |
06/28/2021 | Monte Rosa Therapeutics, Inc. | | Conversion | Series B convertible preferred stock | 4.2M | $0.00 | $0 | By Versant Vantage I, L.P. | 06/28/2021 |
06/28/2021 | Monte Rosa Therapeutics, Inc. | | Conversion | Series C convertible preferred stock | 2.7M | $0.00 | $0 | By Versant Vantage I, L.P. | 06/28/2021 |
06/28/2021 | CRISPR Therapeutics AG | CRSP | Other (disposition) | Common Shares | 615.6k | $0.00 | $0 | See Footnote | 06/28/2021 |
|